贝伐单抗联合卡培他滨一线治疗老年转移性结直肠癌患者的疗效和安全性OACSTPCD
Effect and safety of bevacizumab combined with capecitabine in the treatment of elderly patients with metastatic colorectal cancer
目的:评估贝伐单抗和卡培他滨的联合方案在老年转移性结直肠癌(metastatic colon or rectal cancer,mCRC)患者一线治疗中的疗效和安全性.方法:收集2013年1月至2016年12月入住首都医科大学附属北京友谊医院76例使用贝伐单抗(5～7.5 mg/kg,d1,q3w)联合卡培他滨(1000～1250 mg/m2,bid,d1～14,q3w)一线治疗老年mCRC的病例进行分析,分析疗效及不良反应(adverse ev…查看全部>>
Objective: To evaluate the efficacy and safety of bevacizumab and capecitabine in the first-line treatment of elderly patients with metastatic colorectal cancer (mCRC). Methods: A total of 76 elderly patients with metastatic colorectal cancer first-line treated with (5-7.5 mg/kg, d1, q3w) combined with capecitabine (1000-1250 mg/m2, bid, d1-14, q3w) between January 2013 and December 2016 were collected. The efficacy and adverse events (AEs) were carefully an…查看全部>>
赵磊;王婧;车娟娟;李卉惠;曹邦伟
首都医科大学附属北京友谊医院肿瘤中心,北京 100050首都医科大学附属北京友谊医院肿瘤中心,北京 100050首都医科大学附属北京友谊医院肿瘤中心,北京 100050首都医科大学附属北京友谊医院肿瘤中心,北京 100050首都医科大学附属北京友谊医院肿瘤中心,北京 100050
转移性结直肠癌联合化疗老年患者
metastatic colorectal cancercombined chemotherapyelderly patients
《临床与病理杂志》 2017 (8)
1629-1633,5
北京市优秀人才培养资助 (2014000021469G268),北京友谊医院院启动基金 (yyqdkt 2015-10).This work was supported by the Beijing Talents Fund (2014000021469G268), Rising Star Program from Beijing Friendship Hospital, CMU (yyqdkt 2015-10), China.
评论